Key facts
- Xfinito Biodesigns’s last known valuation is $1.0M (Jan 2022).
- It has raised $380K.
- Notable investors include Campus Fund (India), Atal-GreatLakes Balachandran Incubator, DERBI Foundation, Foundation for Science Innovation and Development, I-Venture @ISB — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Xfinito Biodesigns
- ·The full record, as it builds
Funding rounds
No funding rounds for Xfinito Biodesigns are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Xfinito Biodesigns
Developer of a healthcare tech platform intended to specialize in neuromorphic computing for revolutionizing neurological diseases, with an initial focus on stroke management. The company's artificial intelligence-based platform is centered around feedback from neurons and muscles, consisting of embedded sensors like pressure, temperature, impedance measurement, and muscle response to physical stimuli, enabling patients to prevent diabetic foot ulcers and monitor the progression of neuropathy.
- Sector
- Healthcare
- HQ
- Bangalore, India
- Founded
- 2019
- Employees
- 9
- Website
- zeuron.ai/
- Ownership
- Privately Held (backing)
Xfinito Biodesigns doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Xfinito Biodesigns shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Xfinito Biodesigns in its N-PORT filings yet. We sweep new filings monthly.